Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27727847 | 0.87 | TSHR (0.41) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL6278988 | 0.81 | MMP13 (0.49) | HDAC1HDAC6HDAC11HDAC8HDAC3 | |
| SCHEMBL871622 | 0.79 | TLR4 (0.50) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL6266739 | 0.76 | MMP9 (0.44) | HDAC8MMP13MMP2MMP1MMP8 | |
| SCHEMBL27707118 | 0.72 | TAS2R14 (0.43) | ALDH1A1MAPTHPGDFKBP1A | |
| SCHEMBL27625061 | 0.67 | HPGD (0.33) | HPGDHSD17B10FKBP1A | |
| SCHEMBL27883083 | 0.65 | TLR4 (0.41) | HDAC4CA1CA2ALDH1A1MAPT | |
| SCHEMBL28021174 | 0.65 | TSHR (0.44) | MMP13MMP2MMP1MMP8CA1 | |
| SCHEMBL21234184 | 0.64 | HPGD (0.51) | MMP13MMP2MMP1MMP8CA1 | |
| SCHEMBL31435683 | 0.64 | CA1 (0.47) | MMP13MMP2MMP1MMP8CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596846-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | claimed |
| WO-2004073599-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | AGOURON PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004093860-A1 | INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | TIMP3, MMP2, MMP7 | HDAC1 128/4885HDAC6 102/4885HDAC11 387/4885 |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | ACE, ACE2, PRSS3 | HDAC1 834/4885HDAC6 1375/4885HDAC11 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.